Pharmacokinetics and pharmacodynamics of levodopa
Identifieur interne : 000D09 ( Main/Exploration ); précédent : 000D08; suivant : 000D10Pharmacokinetics and pharmacodynamics of levodopa
Auteurs : John G. Nutt [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008.
English descriptors
Abstract
The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half‐life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the so‐called short‐duration response. These features are the basis of motor fluctuations that complicate long‐term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short‐duration response and conceivably part of the short‐duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22037
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetics and pharmacodynamics of levodopa</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2BA7165434F86FDEC7973E04305D002F535047C3</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22037</idno><idno type="url">https://api.istex.fr/document/2BA7165434F86FDEC7973E04305D002F535047C3/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002494</idno><idno type="wicri:Area/Main/Curation">002164</idno><idno type="wicri:Area/Main/Exploration">000D09</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pharmacokinetics and pharmacodynamics of levodopa</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Oregon Health & Science University, Parkinson Disease Research, Education and Clinical Center, Portland VA, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region><settlement type="city">Portland</settlement></placeName><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008">2008</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S580">S580</biblScope><biblScope unit="page" to="S584">S584</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2BA7165434F86FDEC7973E04305D002F535047C3</idno><idno type="DOI">10.1002/mds.22037</idno><idno type="ArticleID">MDS22037</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>dyskinesia</term><term>levodopa</term><term>motor fluctuations</term><term>short‐duration response</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half‐life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the so‐called short‐duration response. These features are the basis of motor fluctuations that complicate long‐term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short‐duration response and conceivably part of the short‐duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Oregon</li></region><settlement><li>Portland</li></settlement><orgName><li>Université des sciences et de la médecine de l'Oregon</li></orgName></list><tree><country name="États-Unis"><region name="Oregon"><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D09 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D09 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2BA7165434F86FDEC7973E04305D002F535047C3
|texte= Pharmacokinetics and pharmacodynamics of levodopa
}}
| This area was generated with Dilib version V0.6.23. |  |